Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002044933 | SCV002116546 | uncertain significance | Retinoblastoma | 2021-10-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.His483 amino acid residue in RB1. Other variant(s) that disrupt this residue have been observed in individuals with RB1-related conditions (PMID: 11480772, 21538077, 28193182), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This missense change has been observed in individual(s) with head and neck cancer (PMID: 24888624). This variant is not present in population databases (ExAC no frequency). This sequence change replaces histidine with leucine at codon 483 of the RB1 protein (p.His483Leu). The histidine residue is highly conserved and there is a moderate physicochemical difference between histidine and leucine. |